TP53 and breast cancer: The presence of true mosaic TP53 alterations should be considered in patients with tumours strongly suggestive of a disease-causing TP53 variant, such as childhood ACC, choroid plexus carcinoma, breast cancer before 31 years of age or with multiple primary tumours belonging to the TP53 core tumour spectrum [13].